Neuroendocrine cancer medicine

One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.

They change related to the disease progression, regardless therapy. Some of the drugs neuroendocrine cancer medicine are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.

  1. Human papillomavirus infection effects
  2. Ovarian cancer abdominal pain
  3. Papiloma krema banja luka
  4. Papiloma laringeo y pulmonar

Material and Methods. All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from neuroendocrine cancer medicine after 2 years.

No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, neuroendocrine cancer medicine the disease progression.

The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.

This article provides an overview of the current state of the imaging modalities neuroendocrine cancer medicine for primary tumor visualization, staging and follow-up. Detection of NETs and patient monitoring relies mainly on anatomical imaging such as computed tomography CTmagnetic resonance imaging MRIand ultrasonography US under certain conditions. Molecular imaging techniques in combination with CT or MRI hybrid imaging greatly benefit neuroendocrine cancer medicine management, including better localization of occult tumors and better staging. Diagnosis of patients with NETs is a complex process and, it is unlikely that any single diagnostic modality to be effective.

Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S.

Revista Romana de Medicina de Laborator

Karzinoide tumoren des dunndarms. Frank Z Pathol.

neuroendocrine cancer medicine

Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles.

hpv impfung cervarix nebenwirkungen hpv genital warts lead to cancer

Ann N Y Acad Sci. Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.

neuroendocrine cancer medicine

CO; 8. Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor.

Most Downloaded Articles

Rom J Morphol Embryol. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose.

  • Mam v tele parazity

J Emerg Med. Biochemical testing for neuroendocrine tumors.

neuroendocrine cancer medicine papillary lesion with atypical ductal hyperplasia

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Neuroendocrine cancer medicine North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental neuroendocrine cancer medicine Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

NEUROENDOCRINE TUMORS: CHOOSING APPROPRIATE IMAGING METHODS | The Medical-Surgical Journal

Acta Oncol. Long-term clinical outcome of somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma.

neuroendocrine cancer medicine cancer bilio pancreatique

Ann Oncol. Predictive factors of efficacy of neuroendocrine cancer medicine somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.